Showing results (181-190 of 324) with videos related to

Sort By:
Pageof 33
International Journal of Radiation Oncology, Biology, Physics|July 1, 1989
Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustmentP Workman, R Ward, T S Maughan, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Lack of stereoselectivity in the pharmacokinetics and metabolism of the radiosensitizer Ro 03-8799 in manP Workman, H F Newman, N M Bleehen, et al.
Anti-Cancer Drug Design|September 1, 1996
Synthesis and antiproliferative activity of tyrphostins containing quinoline moietiesV G Brunton, M J Lear, P McKeown, et al.
Biochemical Pharmacology|December 1, 1992
The enzymology of doxorubicin quinone reduction in tumour tissueJ Cummings, L Allan, N Willmott, et al.
British Journal of Cancer|November 24, 2004
Clinical anticancer drug development: targeting the cyclin-dependent kinasesC Benson, S Kaye, P Workman, et al.
Psychological Medicine|September 9, 2016
A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onsetA Sibelli, T Chalder, H Everitt, et al.
International Journal of Radiation Oncology, Biology, Physics|May 1, 1990
Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508)T S Maughan, H F Newman, N M Bleehen, et al.
Oncology Reports|May 20, 2011
Antitumor effect of trimelamol against human breast carcinoma xenografts in nude miceY Yamada, T Kubota, Y Hoshiya, et al.
Cancer Chemotherapy and Pharmacology|June 10, 1998
Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patientsP Beale, I Judson, J Hanwell, et al.
Cancer Chemotherapy and Pharmacology|December 4, 2009
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial originM Ranson, H Shaw, J Wolf, et al.
Pageof 33